Company news

Processa Pharmaceuticals, Inc. news in 2020

Processa Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

November 11, 2020

Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

November 4, 2020

Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5: 30 p.m. ET

November 2, 2020

Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer

October 12, 2020

Processa Pharmaceuticals Closes $19.2 Million Public Offering

October 5, 2020

Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market

October 1, 2020

Processa Pharmaceuticals entered into a contingent precedent in-licensing agreement with Elion Oncology for the development of eniluracil (PCS6422) for the treatment of advanced gastrointestinal tumors

August 26, 2020

Processa Pharmaceuticals enters into a licensing agreement with Yuhan corporation for the development of YH12852 in functional gastrointestinal disorders

August 19, 2020

Processa Pharmaceuticals announces that it has entered into an agreement with Aposense, LTD to license in the next generation irinotecan drug

May 31, 2020

Processa Pharmaceuticals to move forward with a PCS499 Phase 3 trial after a successful FDA meeting

March 29, 2020

Processa Pharmaceuticals announces results from the Phase 2 study in necrobiosis lipoidica

March 16, 2020

Processa Pharmaceuticals announces formation of its medical and scientific advisory board

March 4, 2020

Processa Pharmaceuticals appoints Geraldine Pannu as an independent director to the board of directors

February 12, 2020

Decks in 2020